In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Cytokine Therapies

Edited by Edited by Raymond P. Donnelly (Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland)
Cytokine Therapies

Published: December 2009

Volume 1182

This Annals volume includes presentations by experts from academia, industry and government on the scientific and clinical basis for the successes and failures of recombinant cytokine therapies.
Learn More

Cytokines are protein messengers responsible for cellular communication with great therapeutic potential to control inflammatory and immune disorders such as cancer, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Despite the solid scientific rationale for this therapeutic promise, many cytokine-related therapies have failed to establish clinical utility.In March 2009, international experts from academia, industry, and government convened to discuss the scientific and clinical basis for the successes and failures of recombinant cytokines and cytokine antagonists as therapeutic agents and possible strategies for improving their clinical success. This volume includes extended versions of key presentations at the meeting.